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INTRODUCTION 
Thalassemia is the most common genetic 
disorder worldwide and is regarded as an 
important problem in public health issues in 
the Mediterranean region There are over 
20,000 people of different ages with 
thalassemia major in Iran with a prevalence of 
one to ten percent in different parts of Iran 
Nowadays, with improvements in the 
therapeutic strategies of patients with  
beta-thalassemia, these patients have a longer 
life expectancies and the prolonged survival of 
these patients makes their quality of life (QoL) 
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ABSTRACT 
Background and aims: Nowadays introduction of regular blood transfusion therapy has 
obviously improved the life expectancy of patients with thalassemia. However, these 
patients face with newer challenges which influence their quality of life (QoL). In this 
study, the aim of this study was to measure QoL among patients with β-thalassemia 
major (β-TM). 
Methods: A cross-sectional study was done at the thalassemia centre of Shahrekord 
University of Medical Sciences. All the forty patients with β-thalassemia which were 
more than 12 years old referred to blood transfusion and participated in this study. Then, 
they were asked to fill out the Short Form Health Status Survey (SF-36) questionnaire. 
The questionnaire evaluates 8 health areas including physical functioning (PF), role-
physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning 
(SF), role-emotional (RE) and mental health (MH). The scores of each participant were 
calculated and data were analyzed using SPSS. 
Results: There were 18 men and 22 women, and the mean age was 21.69±5.74 years  
(range 12-38). No significant difference was seen in QoL between men and women 
(68.72±19.79 versus 67.47±18.80, P=0.84). The mean±SD score of PF, RP, BP, GH, VT, 
SF, MH was 80.5±16, 83.75±29.17, 71.94±24.22, 57.48±23.93, 54.36±22.51, 
68.94±23.37, 66.33±36.04 and 58.51±23.68, respectivly. No significant differences were 
detected in all mentioned scores between men and women (P>0.05). 
Conclusion: Although most of the participants had suitable physical functioning, 
thalassemia had a negative effect on emotional role, social functioning and mental health 
of patients. It shows the importance of psychosocial supports for these patients. 
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as an important issue.
1-4
 There are many 
reasons such as chronicity of the disease, 
treatment costs, absence of sexual 
development, infertility, inability to raise their 
own family and expected early death that 
cause psychosocial problems in patients with 
thalassemia.
3,5
 In order to improve QoL of 
these patients, programs was aimed to provide 
psychological supports  which are needed.
2,6
 
The QoL should be considered as an 
important index of effective treatment. The 
evaluation of QoL differs from other forms of 
medical evaluations in that it focuses on the 
individuals’ own views of their well-being. 
Therefore, determining QoL of these patients 
leads to better understanding of their specific 
needs and using more effective care.
2,7
 
As Iran has a high prevalence of 
thalassemic patients, efforts for improving 
their status especially in psychosocial area 
with effective interventions are needed. In this 
way evaluation of the QoL is the first step in 
this regard. The better we know about their 
QoL, the easier we can make program for 
sufficient interventions for improving these 
patients' status. 
In this study we want to evaluate the 
quality of life among patients with  
beta- thalassemia major in Shahrekord city, 
Iran. 
 
METHODS 
In this cross-sectional study, all the 40 
patients with β-TM who were being transfused 
at the thalassemia ward of Hajar Hospital of 
Shahrekord University of Medical Sciences 
were selected during 2013. All the patients 
were more than 12 years old and had been 
transfusion-dependent. The diagnosis had 
been made according to their hemoglobin 
electrophoresis results. The study protocol was 
approved by the Ethics Committee of 
Shahrekord University of Medical Science. 
The aim of the study was explained for all the 
patients and verbal consents were obtained. 
The patients' demographics information, 
including age, sex and marital status were 
recorded. 
The Persian version of the SF-36 
questionnaire which was already translated 
and validated by Jafari et al with a Cronbach's 
alpha coefficient (a=0.93) was used in this 
study. The SF-36 is a self-administered QoL 
scoring system which consists of eight 
independent scales and two major dimensions. 
The eight multi-item scales include physical 
functioning (PF), role-physical (RP), bodily 
pain (BP), general health (GH), vitality (VT), 
social functioning (SF), role-emotional (RE) 
and mental health (MH).
8
 The first five scales 
are summarized into the physical health 
dimension and the last three scales into the 
mental health dimension.
9
 The score given to 
QoL in each domain varies between zero to 
100; a score close to zero shows a worse QoL 
and the one close to 100 shows a better QoL. 
All patients were asked to fill out the 
questionnaire. Data were analyzed using 
descriptive statistics (frequency, mean, and 
standard deviation) with SPSS software. 
 
RESULTS 
A total of 40 patients were collected and 
participated in this study. All of participants 
filled out the questionnaire. From these,  
18(40%) were males, and 22(60%) were 
females. The mean age of the subjects was 
21.69±5.74 years (ranging from 12-38 years). 
Two (5%) were married and 38 (95%) were 
single. 
Total QoL of the participants was not 
high (68.06±18.96) and it was not 
significantly different between male and 
female participants (68.72±19.79 vs 
67.47±18.80, P=0.84). 
The mean GH score was 57.48±23.93. 
Regarding general health, the patients asked 
about their overall general health. Three 
(7.5%) patients said that their GH was 
excellent, 13(32.5%) felt very good, 12(30%) 
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felt good, 9(22.5%) felt fair and 3(7.5%) felt 
bad. 
The mean PF score was 80.5±16. 
Regarding PF, patients were asked about the 
activities such as walking, bathing, dressing 
and climbing stairs. All of participants said 
that there were no limitations for them for 
bathing or dressing, but 9(22.5%) had 
limitations for walking only one block and  
23(57.5%) subjects had limitations for 
climbing several stairs. 
The mean RP score was 83.75±29.17. 
Regarding to this territory, 27(67.5%) subjects 
received 100 scores and only 3(7.5%) got zero 
score. 
The mean BP score was 71.94±24.22. 
Nine(22.5%) patients felt no pain and 2(5%) 
said that pain had adversely interfered with 
their normal work during the past 4 weeks. 
The mean SF score was 68.94±23.37. 
About the question 'Do emotional problems 
interfere with your normal social activities 
with family, friends, neighbors or groups?' 
14(35%) chose the answer "not at al," 
10(25%) chose "slightly," 8(20%) chose 
"moderately", 7(17.5%) answered "sever" and 
1(2.5%) answered "very sever." 
The mean VT score was 54.36±22.51. 
Fifteen (37.5%) subjects received scores 
below 50 in this territory. About the question 
'Did you have a lot of energy?’, a quarter 
(10 subjects) chose the answer "all of the 
time" or "most of the time" and 5 subjects 
chose “none of the time." 
The mean RE score was 66.33±36.04. 
Fifteen (37.5%) participants said that they 
worked less carefully than usual. 
Regarding to MH, the mean score of this 
item was 58.51±23.68.The participants were 
asked to answer if they had been a happy 
person. Thirteen (32.5%) subjects responded 
that they had been happy all of the time or 
most of the time and eight (20%) felt happy 'a 
good bit of time’. Two (5%) said that they had 
never been happy and eight (20%) felt happy a 
little of the time. The others responded "some 
of the time." 
No significant differences were found 
between male and female participants in all 
the mentioned items (P<0.05) (Table-1). 
 
Table 1: Health-related quality of life of the patients with beta-thalassemia major in Shahrekord 
City, Iran 
Variable Total Men Women P 
Physical functioning 80.50±16 79.17±16.89 81.59±15.99 0.646 
Role-physical 83.75±29.17 87.50±27.45 80.68±30.79 0.464 
Bodily pain 71.94±24.22 75.15±20.73 69.45±26.81 0.459 
General health 57.48±23.93 57.37±20.10 57.57±27.14 0.979 
Vitality 54.36±22.51 52.06±23.05  56.14±22.46 0.583 
Social functioning 68.94±23.37 75.34±21.00 61.11±24.21 0.058 
Mental health 58.51±23.68 58.65±24.04 58.41±23.96 0.976 
Role emotional 66.33±36.04 62.96±35.94 63.63±36.96 0.954 
Total SF-36 68.06±18.96 68.72±19.79 67.47±18.80 0.844 
 
DISCUSSION 
Beta-thalassemia is a genetically inherited 
disorder characterized by reduced synthesis of 
the beta-hemoglobin chain which results in 
reduced synthesis of hemoglobin A.
10
 It can 
be a potentially life-threatening disease, but 
advances in treatment have increased life 
expectancy. However, the need for chronic 
blood transfusions and chelation therapy 
remains a burden for these patients.
11
 Despite 
advancements in care, transfusion-dependent 
patients still present complications and often 
suffer from psychological problems. It shows 
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the importance of developing QoL of these 
patients in addition to life support strategies.
10
 
Fourty patients with beta-thalassemia 
who all were transfusion-dependent, took part 
in this study. Most of them were single in 
agreement with other studies.
10,12
 cardiological 
disorders, diabetes mellitus, hepatitis, 
dependency on periodic blood transfusion and 
infertility are the common causes.
5
 
The current study shows intermediate 
mean QoL in patients with major 
thalassemia. This finding is similar to the 
results of some studies conducted in Iran, 
but another study conducted by Haghpanah 
et al shows low mean QoL in these 
patients.
2,5
 Such inequalities are because of 
differences of the physical conditions among 
thalassemic patients. 
Most of the participants showed to have 
higher scores in items evaluating physical 
health than mental health. It can be due to 
regular blood transfusion and using 
deferoxamine which can improve the physical 
health status, but developing mental health is 
depending on social supports.
5,15
 The results 
of this study found that many of the patients 
with thalassemia major suffered from loss of 
energy,  anger and sadness. This might be due 
to the chronicity of the disease, unemployement, 
infertility and many other factors that can 
influence mental health. It is consistent with 
the findings of other studies.
13,14 
These patients 
had low or intermediate mean scores in all 
scales except in PF and RP. Similar to our 
study, Haghpanah et al reported low mean 
scores in other scales except PF in patients 
with thalassemia major.
5
 
Differing from our results, Sobota et al 
found worse QoL and lower scores in 
women.
11
 In the study conducted by 
Haghpanah et al women had lower scores on 
BP and RE.
5
 However, Hadi et al reported 
better scores in women.
16
 Problems resulting 
from thalassemia and its treatment are not 
different between men and women. Equality 
in treatment especially iron chelating can be 
the reason of same scores in men and women 
in this study. 
One limitation of this study was the lack 
of control group for comparing QoL of 
thalassemic patients and normal population. In 
addition, because of unequal culture, these 
findings are not representative of all 
thalassemic patients in Iran. This shows that 
different interventions are needed for 
improving quality of life among these patients 
in different areas and cities and the first step 
for programming these interventions is 
evaluating the quality of life among patients 
with thalassemia. 
 
CONCLUSION 
Β-thalassemia major widely influences on 
Qol of patients. So, health promotion supports 
especially in psychosocial area is needed for 
these patients and focusing on blood 
transfusion or iron chelating agents is not 
sufficient. 
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